Fig. 2

Shrinkage patterns of mass lesions. a Concentric shrinkage (CS): CS to small foci (pretreatment: a well demarcated 47 mm mass, early neoadjuvant therapy [NAT]: tumor size was significantly reduced with only residual enhancement foci < 5 mm), b CS: simple CS (pretreatment: a well demarcated 45 mm mass, early NAT: tumor size decreased to 32 mm without any morphological changes), c CS: CS plus decreased enhancement (pretreatment: an irregular 32 mm mass, early NAT: tumor size decreased to 25 mm with significantly reduced enhancement), d diffuse decrease (DD): CS with surrounding lesions (pretreatment: a 83 mm mass, early NAT: The tumor was distinctly CS with peripherally focal lesions), e DD: shrinkage with residual multinodular lesions (pretreatment: a 60 mm mass, early NAT: tumor splits into uniform fragments mixed with fibrous stroma) f decrease of intensity only (DIO) (pretreatment: an irregular 21 mm mass, early NAT: the degree of enhancement were obviously reduced but unchanged size) and g stable disease (SD) (pretreatment: a 35 mm mass, early NAT: no change)